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Abstract
The Vibrionaceae is comprised of numerous aquatic species and includes several human pathogens, such as Vibrio cholerae,
the cause of cholera. All organisms in this family have two chromosomes, and replication of the smaller one depends on
rctB, a gene that is restricted to the Vibrionaceae. Given the increasing prevalence of multi-drug resistance in pathogenic
vibrios, there is a need for new targets and drugs to combat these pathogens. Here, we carried out a high throughput cell-
based screen to find small molecule inhibitors of RctB. We identified a compound that blocked growth of an E. coli strain
bearing an rctB-dependent plasmid but did not influence growth of E. coli lacking this plasmid. This compound, designated
vibrepin, had potent cidal activity against V. cholerae and inhibited the growth of all vibrio species tested. Vibrepin blocked
RctB oriCII unwinding, apparently by promoting formation of large non-functional RctB complexes. Although vibrepin also
appears to have targets other than RctB, our findings suggest that RctB is an attractive target for generation of novel
antibiotics that only block growth of vibrios. Vibrio-specific agents, unlike antibiotics currently used in clinical practice, will
not engender resistance in the normal human flora or in non-vibrio environmental microorganisms.
Citation: Yamaichi Y, Duigou S, Shakhnovich EA, Waldor MK (2009) Targeting the Replication Initiator of the Second Vibrio Chromosome: Towards Generation of
Vibrionaceae-Specific Antimicrobial Agents. PLoS Pathog 5(11): e1000663. doi:10.1371/journal.ppat.1000663
Editor: Craig R. Roy, Yale University School of Medicine, United States of America
Received July 1, 2009; Accepted October 23, 2009; Published November 20, 2009
Copyright:  2009 Yamaichi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIAID R37 AI-42347 and by HHMI. High throughput screening and medicinal chemistry resources were provided by the
National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NIAID U54 AI057159). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mwaldor@rics.bwh.harvard.edu
¤ Current address: CNRS, Centre de Ge ´ne ´tique Mole ´culaire, UPR 2167, Gif-sur-Yvette, France
Introduction
The Vibrionaceae are a diverse family of bacteria that includes
more than 80 species [1,2]. Vibrios are gram-negative rods that
usually inhabit aquatic habitats, often in association with
eukaryotes. This large family includes important human pathogens
such as V. cholerae, V. parahaemolyticus and V. vulnificus, which can
cause gastrointestinal disorders and other illnesses [2,3]. Vibrio
species are also pathogenic for several economically important
marine organisms; for example farmed shrimp are harmed by V.
harveyi and V. nigripulchritudo [2,4,5].
One notable attribute of the Vibrionaceae is their bipartite
genomes. The genomes of most other c-proteobacteria (such as E.
coli) consist of single circular chromosomes, whereas the genomes
of vibrios are comprised of two circular chromosomes [6]. Studies
of V. cholerae, the agent of cholera, have revealed that different
proteins initiate replication of its two chromosomes. Initiator
proteins bind to and melt origins of replication and also recruit
components of the replisome to the origin [7]. DnaA, a conserved
AAA+ ATPase, is thought to be the initiator of chromosome DNA
replication in most eubacteria [8,9], and several observations
support the idea that DnaA serves as the initiator of replication of
the large V. cholerae chromosome (chrI) as well. The origin of
replication of chrI, oriCI, is similar in sequence to oriC, the origin of
replication of the E. coli chromosome [10], and both contain
several binding sites for DnaA. Replication of oriCI-dependent
minichromosomes is DnaA-dependent [10], and overexpression of
DnaA leads to overinitiation of oriCI [11]. Finally, DnaA can
unwind oriCI but can’t unwind oriCII, the origin of replication of
the small V. cholerae chromosome (chrII) [12].
Several observations suggest that RctB, a 658 amino acid
protein that lacks any known motifs or similarity to characterized
initiators, is the initiator of chrII replication. First, RctB binds to
several sites within oriCII [10]. Second, overproduction of RctB in
V. cholerae promotes overinitiation of chrII and not chrI [11].
Third, RctB is necessary and sufficient to enable replication of
oriCII-based minichromosomes in E. coli, and the copy number of
such minichromosomes increases as the level of RctB is raised
[12,13]. Finally, RctB can unwind oriCII and not oriCI [12].
rctB homologues are encoded by all vibrios that have been tested
but are not found outside the Vibrionaceae [10]. As a conserved and
essential gene product restricted to the Vibrionaceae, RctB might be
an attractive target for new vibrio-specific antibiotics. Given the
increasing prevalence of multi drug resistance in pathogenic
vibrios [14–18], there is a growing need for new drugs to combat
these organisms. Here, we carried out a high throughput cell-
based screen to find small molecule inhibitors of RctB. We
identified a compound that blocks growth of an E. coli strain
bearing an rctB-dependent plasmid but does not influence growth
of E. coli lacking this plasmid. This compound, designated
PLoS Pathogens | www.plospathogens.org 1 November 2009 | Volume 5 | Issue 11 | e1000663vibrepin, also has potent cidal activity against V. cholerae and
inhibits growth of all vibrio species tested. Genetic and
biochemical evidence strongly suggest that this compound,
designated vibrepin, targets RctB. Our findings suggest that RctB
is a useful drug target for the creation of Vibrionaceae-specific
antimicrobial agents.
Results
A candidate RctB inhibitor identified with a high
throughput cell-based screen
We developed a high throughput cell-based screen to identify
small molecule inhibitors of RctB. This assay relied on pYB289, a
small plasmid that contains only oriCII, rctB and a gene (aph) that
confers resistance to kanamycin (Figure 1A). This plasmid can
replicate in E. coli, since expression of rctB in E. coli is sufficient to
enable replication of oriCII-dependent plasmids in this heterolo-
gous host [12,13]. E. coli harboring pYB289 exhibit kanamycin
resistance, and we used kanamycin resistance as a marker of this
plasmid’s replication in our screen. We screened a library of
,138,000 small molecules for compounds that inhibited
growth of E. coli Mach1 harboring pYB289 in the presence of
kanamycin but did not inhibit growth of Mach1 without the
plasmid. Several candidate RctB inhibitors were identified, and
one - 3- (3,4-dichlorophenyl) cyclopropane -1,1,2,2 -tetracarboni-
trile (Figure 1B), designated here as vibrepin (for vibrio replication
inhibitor)- was selected for further study, since its predicted
pharmacologic properties were superior to the others.
Genetic evidence that vibrepin targets RctB
Vibrepin had no effect on the growth (indicated by increased
OD600 nm in cultures) of E. coli strain DH5a (Figure 1C). In
addition,itdidnotinfluencegrowthinthepresenceofkanamycinof
DH5aharboringpWSK129orpYB190,plasmidswithdistinct non-
RctB dependent origins of replication (pSC101 and pUC,
respectively) that contain aph cassettes, and so does not appear to
interfere with establishment ofkanamycin resistance (Figure 1G and
data not shown). However,16 mg/ml vibrepin completely inhibited
Author Summary
Multi-drug resistant bacteria continue to emerge and there
is a pressing need for the development of new antibiotics.
Here, we carried out a cell-based high throughput screen
to identify inhibitors of RctB, the initiator of replication of
the second chromosome found in all the species of the
Vibrionaceae. This family of bacteria includes several
human pathogens, including Vibrio cholerae, the cause of
cholera, as well as several species that damage econom-
ically important marine organisms. We identified a
compound—designated vibrepin—that has potent cidal
activity against V. cholerae and inhibited growth of all
vibrio species tested. Vibrepin blocked RctB unwinding of
the origin of replication of the second V. cholerae
chromosome, apparently by promoting the formation of
large non-functional RctB complexes. Vibrepin represents a
new class of antibiotic that specifically targets a particular
family of microorganisms (the Vibrionaceae). Such targeted
agents will not engender resistance in the normal human
flora or in non-vibrio environmental microorganisms. Thus,
in principle, genes mediating resistance to these com-
pounds will not arise in and be transferred from non-
vibrios to vibrios, perhaps postponing the development of
resistance.
Figure 1. Identification of a small molecule that inhibits RctB-dependent replication. A) Schematic of the RctB-dependent oriCII-bearing
plasmid, pYB289, used in the high throughput screen for small molecule inhibitors of RctB. B) Structure of vibrepin, one of the compounds identified
in the screen. C–G) growth curves of E. coli DH5a harboring no plasmid, pYB289 (encoding wt RctB), pYB340 (encoding RctB[L365I]), pYB344
(encoding RctB [P516Q]) and pWSK129 (a non-oriCII-based plasmid). Thick black lines represent growth in the presence of vibrepin (16 mg/ml) and
gray lines represent growth in the presence of DMSO. Representative growth curves (average of triplicate wells from a plate reader) from 3 or more
independent experiments are presented. The higher initial optical density of the cultures containing vibrepin is due to the incomplete solubility of
this compound in LB media at 16 mg/ml. This is apparent in H) which shows the optical density generated by vibrepin (thick line), or DMSO (thin gray
line) without the addition of cells.
doi:10.1371/journal.ppat.1000663.g001
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dependent plasmid pYB289 for 6 hr (Figure 1D). Some growth of
this strain was detectable after 6 hr, probably because the drug was
no longer present, since these cells did not appear to be resistant to
vibrepin if tested in fresh media.
Although vibrepin-resistant DH5a/pYB289 did not arise in
these assays, growth of DH5a containing one of several derivatives
of pYB289 (pYB340 or pYB344) that encode variants of RctB with
single amino acid substitutions (RctB L365I and P516Q,
respectively, which were identified in an unrelated study, see
materials and methods) was not impaired by vibrepin (Figure 1E
and F). These strains grew as well in the presence of vibrepin as
did DH5a lacking a plasmid. Since the only differences between
strains DH5a/pYB289, DH5a/pYB340 and DH5a/pYB344 are
single amino acid differences in RctB, these observations strongly
support the idea that vibrepin targets RctB.
We also assessed the compound’s effect on growth of DH5a/
pYB289 in the absence of kanamycin. We anticipated that
vibrepin would not inhibit bacterial growth under these condi-
tions, since RctB activity should not be required in the absence of
kanamycin. Unexpectedly, we found that vibrepin impaired the
growth of DH5a/pYB289 even when plasmid replication was not
required. Addition of 16 mg/ml vibrepin to cultures of this strain
lacking kanamycin prevented an increase in OD600 nm for ,2h r
and caused a decrease in the number of viable cells (Figure 2B) but
did not influence growth of DH5a lacking this plasmid (Figure 2A).
Vibrepin also stimulated the loss of pYB289 from DH5a in the
absence of kanamycin selection (Figure 2D). Vibrepin even had a
mild inhibitory effect on the growth of DH5a harboring pYB376,
a pSC101-based vector containing rctB (Figure 2C). Collectively,
these results suggest that production of wild type RctB in the
presence of vibrepin may have toxic effects, at least in E. coli, and
that such effects may contribute to the growth inhibition observed
in the assay used above. However, since vibrepin was a less potent
inhibitor of DH5a/pYB289 growth in the absence of kanamycin
than in its presence, it is likely that vibrepin inhibits growth of this
strain by more than one mechanism.
Biochemical evidence that vibrepin targets RctB
To assess vibrepin’s influence on RctB’s activity as a replication
initiator, we tested the compound’s effects on unwinding of oriCII by
RctB, using a P1 nuclease-based assay. In this assay, the single-
strand specific P1 endonuclease cleaves a plasmid containing oriCII
if it becomes unwound; linearized plasmid is then detected by
agarose gel electrophoresis [12]. As seen in Figure 3A, unwinding of
oriCII by RctB was markedly inhibited by vibrepin. DMSO, the
solvent used to dissolve vibrepin, did not influence RctB unwinding
activity (data not shown). These observations are consistent with the
hypothesis that vibrepin interferes with RctB function as an initiator
of replication by blocking its ability to unwind oriCII.
We also explored whether vibrepin influences the oligomeric
state of RctB. In our ongoing studies of the mechanism of action of
RctB, we found that purified RctB does not pellet after
centrifugation at 20,0006g for 30 min in the absence of DNA.
However, in the presence of 10 mg/ml of vibrepin, ,50% of RctB
was found in the pellet fraction after centrifugation; when higher
amounts of vibrepin were added, most of the RctB added to the
assay pelleted (Figure 3B). In contrast, RctB [P516Q], which
appeared to be resistant to in vivo inhibition by vibrepin
(Figure 1F), was less susceptible than wild type RctB to vibrepin-
induced aggregation in the pelleting assay (Figure 3C). Further-
more, vibrepin did not promote the aggregation of either CpxR
[19] (Figure 3D) or ParA2 (data not shown), DNA-binding
proteins unrelated to RctB. Thus, vibrepin does not indiscrimi-
nately aggregate proteins. The vibrepin solvent DMSO also did
not promote the pelleting of RctB. Together, these findings suggest
Figure 2. Influence of vibrepin on an E. coli strain bearing an RctB-dependent plasmid in the absence of kanamycin. A–C) DH5a (A),
DH5a/pYB289 (B), or DH5a/pYB376 (C) were incubated in LB media in test tubes with either vibrepin (16 mg/ml, thick black lines) or DMSO (gray
lines). OD600 nm and colony forming units (CFU) were determined at the indicated times. Representative growth curves from 3 or more independent
experiments are presented. D) The relative amount of the oriCII-based plasmid pYB289 in DH5a after 4 hr of treatment with vibrepin (16 mg/ml) or
DMSO. The amount of pYB289 relative to chromosomal DNA was determined before (t=0) and 4 hrs after treatment (t=4) using Southern
hybridization. The relative amount of pYB289 at t=0 was set as 1; the mean and standard deviations after 4 hr were calculated from 3 independent
experiments.
doi:10.1371/journal.ppat.1000663.g002
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complexes of RctB that are no longer soluble. Consistent with
these observations, we found that vibrepin increased the apparent
radius of RctB complexes approximately 4-fold in dynamic light
scattering (DLS) assays (from 153 to 588, Figure 3E). The range of
radii of the RctB complexes after addition of vibrepin was narrow,
suggesting that vibrepin promotes the formation of RctB
complexes of a particular stoichiometry rather than random
aggregation of this protein. Although the apparent radius of RctB
[P516Q] was greater than that of wild type RctB, vibrepin only
had a minor effect (from 257 to 370, Figure 3F). Collectively these
observations suggest that vibrepin may interfere with RctB oriCII
unwinding by promoting the formation of non-functional RctB
complexes.
Diverse vibrios are susceptible to vibrepin
RctB is required for replication of V. cholerae chrII and is
hypothesized to govern chrII replication initiation in all other
vibrio species as well, since it is highly conserved. We therefore
assessed whether vibrepin could inhibit the growth of vibrio
species. Vibrepin prevented growth of V. cholerae at doses as low as
1.0 mg/ml (Figure 4A). Used at this concentration, vibrepin
induced stasis; however, at higher doses vibrepin had cidal activity.
At concentrations of 4 mg/ml, vibrepin reduced the numbers of
N16961 colony forming units (CFU) by more the 5 orders of
magnitude within 30 minutes (Figure 4A).
Vibrepin also prevented growth of all additional vibrio species
tested (Table 1). Drug concentrations ranging from 0.4 to 0.8 mg/
ml were sufficient to inhibit the growth of the three major human
vibrio pathogens V. cholerae, V. parahaemolyticus and V. vulnificus,a s
well as the shrimp pathogen V. nigripulchritudo (Table 1). In contrast,
vibrepin concentrations ,13 mg/ml did not inhibit growth of any
of the E. coli strains we tested, including several pathogenic strains,
and most E. coli strains were resistant to at least 16 mg/ml of
vibrepin (Table 1). Together these observations are consistent with
the idea that vibrepin targets RctB, a vibrio-specific essential
protein. However, we also observed that vibrepin inhibited growth
of Bacillus subtilis and Staphylococcus aureus (Table 1), two Gram-
positive species that lack RctB homologues. Thus, it appears that
some organisms contain vibrepin targets other than RctB. The
vibrepin target(s) in these Gram-positive bacteria has yet to be
defined.
Several approaches were taken to confirm the target of vibrepin
in V. cholerae. First, we repeatedly screened for V. cholerae mutants
that had spontaneously acquired resistance to vibrepin; however,
resistant colonies were never obtained. We were not able to
introduce point mutations in the chromosomal copy of rctB.
However, we transformed V. cholerae with plasmids encoding alleles
of RctB that were resistant to vibrepin in E. coli (pYB303 and
pYB345, encoding RctB L365I and P516Q, respectively), and
assessed whether they conferred resistance. Exogenous production
of RctB from these plasmids (which did not alter V. cholerae’s
growth rate) did not render cells resistant (data not shown),
suggesting that the presence of wt RctB results in dominant
sensitivity, as might be expected given viprepin’s toxicity in
DH5a/pYB289 even in the absence of plasmid selection.
Alternatively, V. cholerae may contain vibrepin targets in addition
to RctB, which confer sensitivity even in the presence of resistant
rctB alleles. Such targets may be related to the non-RctB targets
that must exist in Gram-positive organisms.
Vibrepin promotes RctB aggregation in vivo
We used an RctB-GFP fusion protein to explore whether
vibrepin altered the subcellular distribution of RctB in V. cholerae.
We constructed a strain where rctB-gfp is expressed from the native
rctB promoter by introducing a gene encoding GFP in-frame at the
39 end of rctB. Since this rctB-gfp fusion is the only copy of rctB in
the cell and this strain had wild type growth (data not shown), the
Figure 3. Vibrepin interferes with RctB oriCII opening activity and promotes formation of RctB complexes. A) Influence of vibrepin
(10 mg/ml) on the oriCII unwinding activity of RctB. Representative results from 3 experiments are shown. B–D) Sedimentation of 10 mM of RctB (B),
RctB[P516Q] (C) or CpxR (D) alone, with DMSO or with different concentrations of vibrepin. After centrifugation the pellet fraction (P) and the
supernatant fraction (S) were loaded on a NuPage SDS gel and stained with Coomassie Blue. E, F) DLS measurements of molecular mass distributions
of RctB (E) and RctB[P516Q] (F) preincubated with or without vibrepin; gray circles, RctB alone; black squares, RctB + vibrepin (10 mg/ml); open circles,
RctB[P516Q] alone; diamonds, RctB[P516Q] + vibrepin (10 mg/ml).
doi:10.1371/journal.ppat.1000663.g003
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distribution of RctB-GFP was generally diffuse, though small foci,
usually near mid cell, were occasionally observed (Figure 4B). One
hour after addition of 1 mg/ml of vibrepin, the diffuse pattern of
RctB-GFP fluorescence was no longer observed; instead, large
puncta of RctB-GFP were seen (Figure 4C). In control
experiments, we found that vibrepin treatment did not alter the
pattern of untagged GFP fluorescence (Figure 4D and E),
consistent with our observation that vibrepin does not lead to
indiscriminate aggregation of proteins in vitro. These data suggest
that the RctB complexes induced by vibrepin in vitro may be a
reflection of its mode of action in vivo, and that vibrepin’s toxicity
for V. cholerae may result, at least in part, from induction of RctB
aggregation.
Comparative analysis of vibrepin and a structural analog
Different vibrepin targets could recognize distinct moieties in
this compound. In an initial structure activity study of vibrepin, we
identified a compound [3-(3-dimethylamino-phenyl)-cyclopro-
pane-1,1,2,2-tetracarbonitrile] (referred to as C2), that is similar
in structure to vibrepin and that contains the same highly
substituted cyclopropane moiety linked to a phenyl group
(compare Figures 5A and 1B). However, C2 did not inhibit
growth of DH5a/pYB289 (Figure 5C) or V. cholerae (Figure 5D).
Since C2 lacks the chlorine substitutions on the phenyl group that
are present in vibrepin, these observations may suggest that the
chlorines in vibrepin are important for its targeting/inhibition of
RctB. However, C2 is not void of antibiotic activity. This
compound inhibited growth of B. subtilis (Figure 5E) and S. aureus
(Figure 5F), albeit with lower potency than vibrepin. Together,
these observations raise the possibility that the additional (non-
RctB) targets of vibrepin may interact with moieties of this
compound that are chemically distinguishable from the parts of
the molecule that inhibit RctB.
Discussion
The development of new agents to combat emerging multidrug
resistant pathogens is a critical challenge for infectious disease
research [20,21]. In recent years, multidrug resistance in V.
cholerae, V. vulnificus, and V. parahaemolyticus, important human
pathogens [14–18], and in vibrio species that damage shellfish and
other marine organisms raised in aquaculture facilities [22] has
been reported. Since RctB is required for replication of the vibrio
second chromosome and conserved among the Vibrionaceae,w e
reasoned that RctB could be a target for development of
antibiotics that specifically target vibrios. Our cell-based screen
for small molecules that inhibited growth of an E. coli strain
containing an oriCII- and RctB-dependent plasmid yielded
vibrepin. Evidence that this compound targets RctB includes the
observations that vibrepin did not inhibit growth of E. coli lacking
the RctB-dependent plasmid or E. coli strains bearing nearly
identical oriCII-dependent plasmids that contained single amino
acid substitutions in RctB. Furthermore, vibrepin blocked
unwinding of oriCII by RctB, apparently by promoting the
formation of non-functional RctB complexes. Finally, vibrepin
inhibited the growth of all vibrio species tested and had potent
cidal activity against V. cholerae. Although vibrepin also appears to
have targets other than RctB, our findings suggest that RctB is an
attractive target for generation of antibiotics that only block
growth of vibrios.
One mechanism by which vibrepin appears to inhibit RctB
function is by promoting formation of RctB complexes. Vibrepin
induction of RctB complexes is relatively specific, as the
compound hardly affected the oligomeric state of RctB[P516Q]
Figure 4. Influence of vibrepin on V. cholerae. A) The optical
density or number of colony forming units in cultures of the V. cholerae
N16961 with the indicated concentrations of vibrepin. Representative
results from at least 3 independent experiments are shown. B–E)
Vibrepin induces aggregation of RctB in vivo. Representative fields of
phase contrast (left) and GFP signal (right) of V. cholerae cells expressing
RctB-GFP (B and C) or untagged GFP (D and E) are shown. (B and D) no
treatment; (C and E) 1 mg of vibrepin was added 1 hr prior to the
imaging. Bar=2 mm.
doi:10.1371/journal.ppat.1000663.g004
Table 1. Minimal inhibitory concentrations (mg/ml)
1 of
vibrepin for various bacteria.
V. cholerae N16961 1.5
V. fluvialis H-08942 2.0
V. parahemolyticus VP47 0.7
V. vulnificus ATCC 27562 0.4
V. nigripulchritudo 0.8
E. coli DH5a .16
E. coli MG1655 .16
EPEC 2348/69 .16
EHEC EDL933 13
B. subtilis PY79 1.0
S. aureus MW2 2.0
1Concentrations of vibrepin that blocked increases in OD600 nm for at least
6 hours. The average values derived from at least 3 experiments are shown.
When 16 mg/ml did not inhibit growth, a value of .16 is shown.
doi:10.1371/journal.ppat.1000663.t001
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unrelated to RctB, CpxR and ParA2. There may be several
consequences of RctB aggregation. First, since vibrepin inhibited
RctB-mediated unwinding of oriCII, RctB complexes may be
unable to initiate chrII replication. Second, since vibrepin
impaired growth of DH5a/pYB289 in the absence of kanamycin,
formation of RctB complexes may be toxic to cells even when
RctB-dependent replication is not required. To date, the
mechanism underlying such toxicity is unknown. Vibrepin also
has targets other than RctB, since this compound inhibited the
growth of bacterial species that do not encode RctB orthologues.
The multiple effects of vibrepin on RctB as well as the possible
existence of a non-RctB vibrepin target(s) in V. cholerae likely
explains our inability to isolate vibrepin-resistant V. cholerae
mutants.
Bacteria-specific mediators of DNA replication might be
expected to be attractive targets for antimicrobial agents. Recently,
O’Donnell and colleagues identified a small molecule that inhibits
the interaction of the E. coli b-clamp with DNA polymerases using
an in vitro biochemical screen [23]. This compound did not
inhibit the interaction of the yeast clamp with polymerase and
hence should not target eukaryotes; however, it is not known
whether this compound inhibits bacterial growth. Inhibitors of
DnaA, the initiator of chromosome DNA replication in almost all
eubacteria, might also have potential as broad spectrum antibiotics
and Skarstad and colleagues reported the development of a high
throughput cell-based assay to identify such inhibitors [24].
However, no antibiotics are currently in use that directly target
bacterial chromosome replication.
We found that RctB activity can be inhibited and thus showed
that thisinitiator of replication of the second vibrio chromosome is a
reasonable target for development of new Vibrionaceae-specific
antimicrobial agents. Even though vibrepin has targets besides
RctB, we anticipate that it will be possible to modify vibrepin or find
new compounds that only target RctB. All antibiotics used in the
clinic today are relatively broad spectrum and target highly
conservedcellularprocesses.Therefore,thesecompoundsinevitably
select for resistant organisms in the normal human flora as well as in
environmental microorganisms after antibiotics are shed into the
environment. Genes that confer resistance can then be horizontally
transmitted from bystander bacteria to pathogens. Vibrionaceae-
specific antibiotics will not engender resistance in the normal
human flora or in non-vibrio environmental microorganisms. Thus,
in principle, genes mediating resistance to these compounds will not
arise in and be transferred from non-vibrios to vibrios, perhaps
postponing the development of resistance. Vibrio–specific agents
may be useful as new agents for aquaculture and in the prevention
and treatment of human vibrioses.
Materials and Methods
High throughput screen for RctB inhibitors
High throughput screening for small molecule inhibitors of
growth of YBA685 in the presence of kanamycin was carried out
at the NSRB screening facility at Harvard Medical School.
YBA685 is E. coli strain Mach1 containing pYB289, an rctB-
dependent vector (Figure 1A). Mach1 (Invitrogen), which grows
faster than most laboratory E. coli strains, was used for the
screening phase of our study to minimize the time required to
detect growth inhibition. For screening, an overnight culture of
YBA685 was inoculated at a 1:500 dilution into LB broth
containing kanamycin (50 mg/ml); the culture was grown at 37uC
until reaching an OD600 nm of ,0.1; then, 30 ml aliquots of the
culture were transferred into 384-well plates. The compound
library (100 nl of 5 mg/ml in DMSO, final concentration
16.7 mg/ml) was pin-transferred to the plates in duplicate. After
the plates were incubated at 37uC for 3 hours, the OD600 nm of the
wells was measured. We used Z-scores [25] to evaluate the growth
Figure 5. Compound C2 does not inhibit growth of V. cholerae but C2 and vibrepin inhibit B. subtilis and S. aureus growth. A) Structure
of compound C2. B–F) Growth curves of the indicated strains with addition of the indicated concentrations (mg/ml) of vibrepin (blue line), C2 (red line)
or DMSO control (gray line). Representative growth curves (average of triplicate wells) from 3 or more independent experiments are presented.
doi:10.1371/journal.ppat.1000663.g005
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deviation of the OD600 nm values from the experimental wells in
each plate were obtained; then Z-scores for each well were
calculated as the difference between the OD600 nm values in each
well and the average OD600 nm divided by the standard deviation.
Compounds with Z-scores below 23 in duplicate plates were
considered positive hits. There were 149 positive hits among
137,694 compounds screened. These compounds were counter-
screened to exclude molecules that inhibited the growth of Mach1
in the absence of pYB289. Ultimately, we identified four
compounds that inhibited growth of YBA685 in the presence of
kanamycin but did not inhibit Mach1 growth. Vibrepin (CID
2803695) and C2 were purchased in milligram quantities from
Maybridge (Tintagel, UK) and Sigma-Aldrich (St. Louis, MO),
respectively. All compounds were dissolved at 50 mg/ml concen-
tration in DMSO and stored at 220uC.
Strains and plasmids
The strains and plasmids used in this study are listed in Table 2
and 3, respectively.
As part of an on-going project to study oriCII-based replication,
we have isolated a series of mutant oriCII-based plasmids that
contain rctA, a negative regulator of RctB, and mutations in rctB
(see Materials and Methods of ref. [12]). These mutant rctB alleles
can support replication of oriCII, at least in E. coli. We tested the
sensitivity of DH5a harboring several of these mutant oriCII
plasmids to vibrepin and found that plasmids A-52 and A-57
containing rctB[L365I] and [P516Q] respectively confer resistance
to the compound. rctA was deleted from A-52 and A-57, yielding
pYB340 and pYB344 respectively, using the QuickChange XL
Site Directed Mutagenesis Kit (Stratagene). The later 2 plasmids
are otherwise identical to pYB289, which contains wild type rctB.
The copy numbers of pYB289, pYB340 and pYB344 in E. coli
DH5a were approximately the same and the growth rates of
DH5a bearing any of these 3 plasmids were indistinguishable. To
create rctB [L365I] or rctB [P516Q] expression vectors, the
relevant rctB variant was PCR amplified and then inserted into
pGZ119EH as previously described [12]. rctB [P516Q] was
inserted into pET28b (Novagen) (yielding pYB346), for high level
expression of C-terminal His tagged RctB [P516Q]. All the
relevant DNA sequences of all vectors used in this study were
determined. The sequences of the PCR primers used in this study
are available upon request.
A V. cholerae strain containing a rctB-gfp translational fusion in
the rctB locus and under the control of the native rctB promoter
(YBB874) and a strain harboring gfp gene inserted in the lacZ locus
under the control of the Plac promoter (YBB182) were constructed
by allele exchange techniques using pCVD442-based plasmids
(pYB364 and pJZ111, respectively) as described [26].
Growth curves
A SynergyHT microplate reader (BioTek, Winooski, VT) was
used to determine the growth kinetics shown in Figures 1 and 5. In
these experiments, overnight cultures were diluted 1:200 and then
incubated for 9 hours. For the growth curves shown in Figures 2
and 4A, overnight cultures were diluted into fresh media in test
tubes and OD600 nm and CFU were determined at the indicated
time points. All cultures were grown in LB media at 37uC except
Tryptic Soy Broth (BD) was used for S. aureus cultures and LB
containing 0.5 M NaCl was used for V. nigripulchritudo cultures
which were grown at 30uC.
Quantification of oriCII plasmid
The copy numbers of oriCII-based plasmids pYB340 and
pYB344 relative to pYB289 were measured by quantitative PCR
as described previously [12]. For Figure 2D, Southern hybridiza-
tion of total genomic DNA was used to quantify pYB289 plasmid
Table 2. Strains used in this study.
Strain Relevant characteristics
Sources/
References
mach1 invitrogen
YBA601 DH5a/pYB289 This study
YBA685 mach1/pYB289 This study
YBA796 DH5a/pYB340 This study
YBA803 DH5a/pYB344 This study
EHEC EDL933 [27]
EPEC 2348/69 [28]
N16961 [29]
YBB182 N16961 lacZ::gfp This study
YBB697 N16961/pYB303 This study
YBB815 N16961/pYB345 This study
YBB874 N16961 rctB-gfp This study
V. nigripulchritudo [5]
V. parahaemolyticus VP47 O3:K6 clone [30]
V. vulnificus ATCC 27562 [31]
V. fluvialis H-08942 [32]
B. subtilis PY79 [33]
S. aureus MW2 [34]
doi:10.1371/journal.ppat.1000663.t002
Table 3. Plasmids used in this study.
Plasmid Relevant characteristics
Sources/
References
A-52 rctB L365I oriCII rctA aph This study
A-57 rctB P516Q oriCII rctA aph This study
pCVD442 Allele exchange vector, Amp
R sacB mob
+ [35]
pET28b IPTG inducible expression vector Novagen
pET-RctB pET28b rctB [12]
pGZ119EH IPTG inducible expression vector [36]
pJZ111 pCVD442 derivative to construct lacZ::gfp [37]
pOriII pBR332 oriCII [12]
pWSK129 pSC101 ori aph [38]
pYB190 pUC ori aph [26]
pYB289 rctB oriCII aph [12]
pYB303 pGZ119 rctB [L365I] This study
pYB340 rctB L365I oriCII aph This study
pYB344 rctB P516Q oriCII aph This study
pYB345 pGZ119 rctB [P516Q] This study
pYB346 pET28b rctB [P516Q] This study
pYB364 pCVD442 derivative to construct rctB-gfp
chromosomal fusion
This study
pYB376 pWSK129 rctB This study
doi:10.1371/journal.ppat.1000663.t003
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and untreated cells. A ,600 bp DNA fragment of rctB was used as
a probe for pYB289 and a similar sized narW fragment was used as
a probe for the E. coli chromosome. Probe preparation and
detection were carried out with the ECL Direct nucleic acid
labeling and detection system (GE Healthcare) according to the
manufacture’s instructions. Bands were quantified using a Fujifilm
FLA-5100 imager.
P1 nuclease cleavage assay
The P1 nuclease-based assays for RctB unwinding of oriCII-
containing plasmid substrates were performed as described
previously [12]. Briefly, different concentrations of C-terminal
His-tagged versions of RctB was mixed with 150 fmol of pOriII in
50 ml of a solution composed of 10 mM Hepes-KOH (pH 7.6),
8 mMmagnesiumacetate,30%glyceroland 320 mg/mlBSA.After
10 min at 37uC, 1.2 units of P1 nuclease was added to each reaction
for 30 seconds; the reactions were stopped with 40 ml of stop buffer
(25 mM EDTA, 1% SDS). For quantification of the linearized
fraction of the pOriII substrate DNA, an aliquot of the reaction was
electrophoresed on a 0.8% agarose gel and then stained with
ethidiumbromide;theproportionoftheplasmid DNAlinearized by
P1 nuclease was determined using densitometry.
Sedimentation assay
Purified C-terminal His-tagged RctB or RctB[P516Q] (10 mM)
was incubated in 20 ml buffer F (30 mM Tris pH 8, 5 mM MgSO4,
100 mM KCl, 2 mM DTT) in the absence or presence of
compounds for 10 min at 30uC. Reactions were then centrifuged
for 30 min at 4uC at 20,0006g in a refrigerated table top centrifuge.
The supernatant and pellet fractions were resuspended in 1X loading
dye, electrophoresed on SDS PAGE gels and then the amount of
protein in each fraction was determined by coomassie staining.
Dynamic light scattering
DLS assays with a Viscotek 802 (He–Ne laser, 633 nm) were used
to evaluate the effects of vibrepin on the apparent molecular mass of
RctB and RctB[P516Q]. To remove any protein aggregates prior to
theDLSassays,theproteinswerecentrifuged for30 minat20,0006g
and then the supernatants were collected and filtered through a
0.1 mm ultrafree MC Milipore filter. In each assay, 300 ng of protein
was added to a 12 ml reaction in sedimentation buffer F in a quartz
cuvette in presence or absence of compounds. The amplitude plotted
on the y-axis in Figure 3E and F is reflective of the intensity
measurements generated in these experiments; intensity is propor-
tional to the size and concentration of the scattering particles.
Amplitude values were calculated using Omnisize 3.0 software. Each
curve is representative of at least 5 measurements.
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